#ASH25: Will a biotech’s pivot away from obesity let it compete with Novartis in leukemia?news2025-12-08T19:45:58+00:00December 8th, 2025|Endpoints News|
Dyne says Duchenne drug succeeds in pivotal study, heads to FDA for approvalnews2025-12-08T16:25:42+00:00December 8th, 2025|Endpoints News|
BioNTech, OncoC4’s antibody more than halves risk of death in Phase 3 lung cancer trialnews2025-12-08T16:14:27+00:00December 8th, 2025|Endpoints News|
Cogent’s mastocytosis drug continues momentum, helps treat sicker patientsnews2025-12-08T15:51:47+00:00December 8th, 2025|Endpoints News|
#ASH25: Kura, Syndax detail data for rival menin inhibitors as both eye earlier use in AMLnews2025-12-08T15:45:18+00:00December 8th, 2025|Endpoints News|
Updated: Structure Therapeutics’ obesity pill stacks up with Novo and Lilly; Ascletis also reports early resultsnews2025-12-08T14:04:26+00:00December 8th, 2025|Endpoints News|
Updated: Wave Life Sciences’ RNA obesity shot cuts fat and retains muscle, but appears to lag behind Lilly’s for nownews2025-12-08T12:30:29+00:00December 8th, 2025|Endpoints News|
Kymera’s pill looks competitive to Dupixent in Phase 1b eczema studynews2025-12-08T12:00:59+00:00December 8th, 2025|Endpoints News|
Kallyope heads to Phase 3 with migraine drug after mid-stage successnews2025-12-08T11:30:40+00:00December 8th, 2025|Endpoints News|
#ASH25: Star Therapeutics details early data for blood disorder shot, weighs IPOnews2025-12-07T21:57:35+00:00December 7th, 2025|Endpoints News|
